Genmab A/S (GNMSF) Stock Price, News & Analysis

Company Overview

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States. Over its history, the company has established multiple collaborations and licensing agreements with leading pharmaceutical partners—among them Janssen Pharmaceuticals, Novartis, BioNTech and Gilead Sciences—to advance its pipeline and bring products to market. These partnerships have yielded approved therapies and provided Genmab with access to extensive clinical development, regulatory and commercial expertise.

Genmab’s most advanced products include DARZALEX® (daratumumab), an anti-CD38 antibody co-developed and marketed with Janssen that has become a standard of care in multiple myeloma, and Tepezza® (teprotumumab), an anti-IGF-1R antibody approved for thyroid eye disease in collaboration with Horizon Therapeutics. In addition to these approvals, the company is progressing a diversified pipeline of investigational candidates across various hematologic malignancies and solid tumors, including epcoritamab, a bispecific CD3xCD20 antibody in late-stage clinical trials.

Genmab is led by Chief Executive Officer Jan van de Winkel, Ph.D., who has served in the role since 2012 and has overseen the company’s transition from early-stage research to a fully integrated biopharmaceutical enterprise. With a presence in key markets worldwide and a leadership team experienced in antibody science, clinical development and commercialization, Genmab continues to advance its mission of creating innovative antibody therapies to address unmet medical needs.

Key Stats

• Today's Range: $232.50 to $232.50
• 50-Day Range: $232.34 to $298.38
• 52-Week Range: $198.51 to $352.00
• Volume: 254 shs
• Average Volume: 4,945 shs
• Market Capitalization: $14.32 billion
• P/E Ratio: 17.53
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Genmab A/S Stock Analysis - MarketRank™

Genmab A/S scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Genmab A/S.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Genmab A/S is 17.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.56.

Price to Earnings Ratio vs. Sector

The P/E ratio of Genmab A/S is 17.53, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.30.

Price to Book Value per Share Ratio

Genmab A/S has a P/B Ratio of 2.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.24% of the float of Genmab A/S has been sold short.

Short Interest Ratio / Days to Cover

Genmab A/S has a short interest ratio ("days to cover") of 8.19.

Change versus previous month

Short interest in Genmab A/S has recently increased by 2.66%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genmab A/S does not currently pay a dividend.

Dividend Growth

Genmab A/S does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Genmab A/S this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Genmab A/S insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.54% of the stock of Genmab A/S is held by insiders.

Percentage Held by Institutions

Genmab A/S has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 2/17/2026
• Today: 6/03/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:GNMSF
• CIK: 1434265
• Web: www.genmab.com
• Phone: (457) 020-2728
• Fax: 45-7020-2729
• Employees: 3,029
• Year Founded: 1999

Profitability

• EPS (Trailing Twelve Months): $13.26
• Trailing P/E Ratio: 17.53
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $963 million
• Net Margins: 21.05%
• Pretax Margin: 26.51%
• Return on Equity: 15.34%
• Return on Assets: 8.94%

Debt

• Debt-to-Equity Ratio: 0.87
• Current Ratio: 2.18
• Quick Ratio: 2.17

Sales & Book Value

• Annual Sales: $3.72 billion
• Price / Sales: 3.85
• Cash Flow: $14.46 per share
• Price / Cash Flow: 16.08
• Book Value: $88.49 per share
• Price / Book: 2.63

Miscellaneous

• Outstanding Shares: 61,570,000
• Free Float: 60,622,000
• Market Cap: $14.32 billion
• Optionable: Not Optionable
• Beta: 0.81